Zimbabwe is now one of the first countries in the world to start a lenacapavir program, which was made possible through funding from the United States government and The Global Fund.

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price ...

Researchers evaluated the association between the use of various hormonal contraceptives and the risk for surgically treated intracranial meningioma.

Zimbabwe is one of the first countries to introduce the HIV prevention drug lenacapavir. The program aims to target over 46,000 high-risk individuals, backed by U.S. funding and the Global Fund.

Zimbabwe's health authorities on Thursday began administering the long-acting HIV prevention drug lenacapavir, making the country one of the first globally to roll it out as the southern African ...

First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance ...

Concomitant ixekizumab and tirzepatide significantly improved skin clearance and weight reduction in adults with moderate to severe plaque psoriasis.

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.

In the heart of Mississippi, Diana "Di" Fillhart, a vibrant 68-year-old, lives a life defined by purpose and an unwavering ...